Prof. Gary Tse matriculated at Trinity Hall, University of Cambridge in 2005 to read pre-clinical medicine. He subsequently completed his clinical training at Imperial College London, as well as PhD and MD from the University of Cambridge. He is a Professor at the School of Nursing and Health Sciences, Hong Kong Metropolitan University (HKMU), where he served successively as the Associate Dean (Innovations and Research) (2023-2025) and Head of Department of Population Health (2025-present). He is also Distinguished Chair Professor at the Department of Cardiology, Second Hospital of Tianjin Medical University, China and a Visiting Professor at the Faculty of Health and Medical Sciences, University of Surrey. Prior to joining HKMU, Prof. Tse held a joint position as Clinical Reader at the University of Kent (with permanent appointment until retirement age) and Public Health Consultant at the Medway Council in local government, UK. He serves as a Nucleus Committee Member of the Population Health Section, European Association of Preventive Cardiology. He is a Council Member, Secretary and President-Elect of the International Society of Electrocardiology, as well as a Member of the Board of Trustees of the International Society for Holter and Non-invasive Electrocardiology.  He is a Fellow of the Faculty of Public Health, Royal College of Pathologists and Royal College of Physicians, and an elected Member of the European Academy of Sciences and Arts (Class II: Medicine). He has been listed on the World’s Top 2% Scientists Released by Stanford University for the Cardiovascular System & Hematology subfield since 2020. He is ranked 26th on the Top Cardiovascular Researchers from China in 2023. He was placed Top 0.05% scientists globally, ranking 87th globally for cardiology in 2024 by ScholarGPS. He ranked 3rd for cardiology in China in 2025 by AD Scientific Index.  He has an H-index of 68 and has obtained more than HK$130 million in research-related funding. He leads the Hong Kong Risk Modelling Team focusing on the use of big data and artificial intelligence for the development of predictive models for estimating biological age and risk prediction of cardiovascular and cerebrovascular diseases. He previously co-led a study into the adverse effects of systemic corticosteroids in COPD under OPRI and AstraZeneca.